Emerging drugs for head and neck cancer

Bibliography

• GILLISON M, WM K, CAPONE R et al.: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J. Natl. Cancer Inst. (2000) 92:709-720.
   PubMed Web of Science ®Google Scholar
• MORK J, LIE K, GLATTRE E et al.: Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. (2001) 344:1125-1131.
   PubMed Web of Science ®Google Scholar
• WEINBERGER PM, YU Z, HAFFTY BG et al.: Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J. Clin. Oncol. (2006) 24(5):736-747.
   PubMed Web of Science ®Google Scholar
• ANG KK, HARRIS J, GARDEN AS et al.: Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group Phase II trial 99-14. J. Clin. Oncol. (2005) 23(13):3008-3015.
   PubMed Web of Science ®Google Scholar
• FORASTIERE A, KOCH W, TROTTI A, SIDRANSKY D: Medical progress: head and neck cancer. N. Engl. J. Med. (2001) 345(26):1890-1900.
   PubMed Web of Science ®Google Scholar
• CHAO KS, OZYIGIT G, BLANCO AI et al.: Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume. Int. J. Radiat. Oncol. Biol. Phys. (2004) 59(1):43-50.
   PubMed Web of Science ®Google Scholar
• CHAO KS, MAJHAIL N, HUANG CJ et al.: Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother. Oncol. (2001) 61(3):275-280.
   PubMed Web of Science ®Google Scholar
• FORASTIERE AA, GOEPFERT H, MAOR M et al.: Concurrent chemotherapy and radiotherapy for organ preservation in advanced larynx cancer. N. Engl. J. Med. (2003) 349(1):2091-2098.
   PubMed Web of Science ®Google Scholar
• AL-SARRAF M, LEBLANC M, SHANKER GIRI P et al.: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J. Clin. Oncol. (1998) 16:1310-1317.
   PubMed Web of Science ®Google Scholar
• PIGNON J, BOURHIS J, DOMENGE C, DESIGNE L: Chemotherapy added to locoregional treatment for head and neck squamous-cell cancer: three meta-analysis of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet (2000) 355:949-955.
   PubMed Web of Science ®Google Scholar
• CALAIS G, ALFONSI M, BARDET E et al.: Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced stage oropharynx carcinoma. J. Natl. Cancer Inst. (1999) 91:2081-2086.
   PubMed Web of Science ®Google Scholar
• BERNIER J, DOMENGE C, OZSAHIN M et al.: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. (2004) 350:1945-1952.
   PubMed Web of Science ®Google Scholar
• COOPER J, PAJAK TF, FORASTIERE A et al.: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N. Engl. J. Med. (2004) 350:1937-1944.
   PubMed Web of Science ®Google Scholar
• ADELSTEIN D, LI Y, ADAMS G et al.: An intergroup Phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J. Clin. Oncol. (2003) 21:92-98.
   PubMed Web of Science ®Google Scholar
• VOKES E, KIES M, HARAF D et al.: Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J. Clin. Oncol. (2000) 18:1652-1661.
   PubMed Web of Science ®Google Scholar
• ANG KK, ANDRATSCHKE NH, MILAS L: Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int. J. Radiat. Oncol. Biol. Phys. (2004) 58(3):959-965.
   PubMed Web of Science ®Google Scholar
• BONNER JA, DE LOS SANTOS J, WAKSAL HW, NEEDLE MN, TRUMMEL HQ, RAISCH KP: Epidermal growth factor receptor as a therapeutic target in head and neck cancer. Semin. Radiat. Oncol. (2002) 12(3 Suppl. 2):11-20.
   PubMed Web of Science ®Google Scholar
• POMERANTZ RG, GRANDIS JR: The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy. Semin. Oncol. (2004) 31(6):734-743.
   PubMed Web of Science ®Google Scholar
• GRANDIS JR, TWEARDY DJ: Elevated levels of transforming growth factor-α and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. (1993) 53(15):3579-3584.
   PubMed Web of Science ®Google Scholar
• COHEN EE, ROSEN F, STADLER WM et al.: Phase II trial of ZD-1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. (2003) 21(10):1980-1987.
   PubMed Web of Science ®Google Scholar
• SOULIERES D, SENZER NN, VOKES EE, HIDALGO M, AGARWALA SS, SIU LL: Multicenter Phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J. Clin. Oncol. (2004) 22(1):77-85.
   PubMed Web of Science ®Google Scholar
• TRIGO J, HITT R, KORALEWSKI P et al.: Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): results of a Phase II study. Proc. Am. Soc. Clin. Oncol. (2004):abstract 5502.
   Google Scholar
• HERBST RS, ARQUETTE M, SHIN DM et al.: Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J. Clin. Oncol. (2005) 23(24):5578-5587.
   PubMed Web of Science ®Google Scholar
• PFISTER DG, SU YB, KRAUS DH et al.: Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot Phase II study of a new combined-modality paradigm. J. Clin. Oncol. (2006) 24(7):1072-1078.
   PubMed Web of Science ®Google Scholar
• BONNER JA, HARARI PM, GIRALT J et al.: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. (2006) 354(6):567-578.
   PubMed Web of Science ®Google Scholar
• LEON X, HITT R, CONSTENLA M et al.: A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin. Oncol. (R. Coll. Radiol.) (2005) 17(6):418-424.
   PubMed Web of Science ®Google Scholar
• BURTNESS B, GOLDWASSER MA, FLOOD W, MATTAR B, FORASTIERE AA: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. (2005) 23(34):8646-8654.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J: Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. (1971) 285(21):1182-1186.
   PubMed Web of Science ®Google Scholar
• SEIWERT T, HARAF D, COHEN E: A Phase I study of bevacizumab (B) with fluorouracil (F) and hydroxyurea (H) with concomitant radiotherapy (X) (B-FHX) for poor prognosis head and neck cancer (HNC). J. Clin. Oncol. (ASCO Annual Meeting Proceedings Part I) (2006) 24(18S):5530.
   Google Scholar
• WEDGE SR, OGILVIE DJ, DUKES M et al.: ZD-6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. (2002) 62(16):4645-4655.
   PubMed Web of Science ®Google Scholar
• WILLIAMS KJ, TELFER BA, BRAVE S et al.: ZD-6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin. Cancer Res. (2004) 10(24):8587-8593.
   PubMed Web of Science ®Google Scholar
• VIDAL M, WELLS S, RYAN A, CAGAN R: ZD-6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Cancer Res. (2005) 65(9):3538-3541.
   PubMed Web of Science ®Google Scholar
• NELSON MH, DOLDER CR: Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann. Pharmacother. (2006) 40(2):261-269.
   PubMed Web of Science ®Google Scholar
• ABIDOYE O, COHEN E, WONG S: A Phase II study of lapatinib (GW-572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). J. Clin. Oncol. (ASCO Annual Meeting Proceedings Part I) (2006) 24(18S):5568.
   Google Scholar
• HARRINGTON K, BOURHIS J, NUTTING M: A Phase I, open-label study of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). J. Clin. Oncol. (ASCO Annual Meeting Proceedings Part I) (2006) 24(18S):5553.
   Google Scholar
• WIRTH LJ, HADDAD RI, LINDEMAN NI et al.: Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. (2005) 23(28):6976-6981.
   PubMed Web of Science ®Google Scholar
• POSNER MR, HADDAD RI, WIRTH L et al.: Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin. Oncol. (2004) 31(6):778-785.
   PubMed Web of Science ®Google Scholar
• HITT R, LOPEZ-POUSA A, MARTINEZ-TRUFERO J et al.: Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J. Clin. Oncol. (2005) 23(34):8636-8645.
   PubMed Web of Science ®Google Scholar
• VERMORKEN JB, REMENAR E, VAN HERPEN C et al.: Standard cisplatin/infusional 5-fluorouracil (PF) versus docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): a Phase III trial of the EORTC Head and Neck Cancer Group (EORTC No. 24971). Proc. Am. Soc. Clin. Oncol. (2004) 23:5508.
   Google Scholar
• POSNER MR, GLISSON B, FRENETTE G et al.: Multicenter Phase I – II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J. Clin. Oncol. (2001) 19(4):1096-1104.
   PubMed Web of Science ®Google Scholar
• WERNER S: Keratinocyte growth factor: a unique player in epithelial repair processes. Cytokine Growth Factor Rev. (1998) 9(2):153-165.
   PubMed Web of Science ®Google Scholar
• STIFF PJ, EMMANOUILIDES C, BENSINGER WI et al.: Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J. Clin. Oncol. (In Press).
   Google Scholar
• SPIELBERGER R, STIFF P, BENSINGER W et al.: Palifermin for oral mucositis after intensive therapy for hematologic cancers. N. Engl. J. Med. (2004) 351(25):2590-2598.
   PubMed Web of Science ®Google Scholar
• HUANG EY, LEUNG SW, WANG CJ et al.: Oral glutamine to alleviate radiation-induced oral mucositis: a pilot randomized trial. Int. J. Radiat. Oncol. Biol. Phys. (2000) 46(3):535-539.
   PubMed Web of Science ®Google Scholar
• ERICKSON R, ROSS D, MEDINA J: Effects of glutamine on head and neck squamous cell carcinoma. Otolaryngol. Head Neck Surg. (1999) 121(4):348-354.
   PubMed Web of Science ®Google Scholar
• PETERSON D, PETIT R: Phase III study: AES-14 in patients at risk for mucositis secondary to anthracycline-based chemotherapy. ASCO Annual meeting proceedings (2004) 23:abstract 8008.
   Google Scholar